How should abnormal liver function tests (ALT, AST, bilirubin) be managed in a patient receiving enfortumab vedotin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Abnormal Liver Function Tests with Enfortumab Vedotin

When liver function tests become abnormal during enfortumab vedotin therapy, immediately repeat testing within 2-5 days and apply a tiered management algorithm based on ALT/AST elevation magnitude and bilirubin levels, with drug interruption required for ALT/AST >3× baseline (or >5× ULN from normal baseline) and permanent discontinuation for ALT/AST >20× ULN. 1

Initial Assessment and Monitoring

Enfortumab vedotin commonly causes changes in liver function tests, listed as one of the most frequent side effects in both monotherapy and combination therapy with pembrolizumab 2. When LFT abnormalities are detected:

  • Measure comprehensive liver panel: ALT, AST, alkaline phosphatase (ALP), GGT, total bilirubin (TBIL), direct bilirubin (DBL), CK, and INR 1
  • Assess bilirubin fractionation: Direct bilirubin helps distinguish true hepatocellular injury from Gilbert's syndrome or hemolysis 1
  • Note the pattern: Research shows AST levels significantly increase with enfortumab vedotin treatment, while ALT elevations may be less pronounced 3

Algorithmic Management Based on Severity

For ALT/AST Elevations from Normal Baseline:

3-5× ULN (or 3-5× baseline if elevated at start):

  • Repeat blood tests within 2-5 days 1
  • Continue treatment if bilirubin remains normal or at baseline 1
  • If bilirubin is >2× baseline or >2× ULN: Withhold drug and repeat tests within 2-3 days 1

5-20× ULN (or 5-20× baseline):

  • Interrupt or reduce study drug dose 1
  • If bilirubin >2× baseline: Consider permanent discontinuation unless alternative explanation identified 1
  • Initiate close monitoring 2-3 times weekly, adjusting frequency based on clinical scenario 1

>20× ULN (or >20× baseline):

  • Permanent discontinuation regardless of bilirubin level 1

Critical Bilirubin Considerations:

For patients with Gilbert's syndrome, use direct bilirubin >2× baseline as the trigger for action rather than total bilirubin 1. This is essential because total bilirubin fluctuates significantly in these patients and may lead to inappropriate treatment interruptions.

Excluding Alternative Causes

Before attributing LFT abnormalities solely to enfortumab vedotin, systematically exclude:

  • Malignancy progression: Liver metastases are the most common cause of LFT elevations in oncology patients 1
  • Biliary obstruction: Particularly relevant given the cholestatic pattern some patients develop
  • Concomitant medications: Review all prescribed, over-the-counter, herbal, and dietary supplements 1
  • Viral hepatitis: Test for hepatitis A, B, and C if not previously done 4
  • Imaging: Obtain abdominal imaging to assess for metastatic disease, biliary dilatation, or other structural abnormalities 1

The timing of LFT elevations relative to drug initiation, the pattern of injury (hepatocellular vs. cholestatic), and degree of elevation provide important diagnostic clues 1.

Monitoring Frequency and Duration

Initial monitoring schedule:

  • 2-3 times weekly when drug is withheld for significant elevations 1
  • Continue monitoring until resolution or stabilization, regardless of whether drug is discontinued 1
  • Observe for clinical features of hepatic decompensation: ascites, encephalopathy, coagulopathy 1

Rechallenge Considerations

Rechallenge with the same or lower dose may be considered based on benefit-risk assessment if:

  • No alternative explanation was found and LFTs normalized 1
  • The patient had significant clinical benefit before toxicity
  • Close monitoring can be maintained

However, if ALT elevations recur on rechallenge, permanent discontinuation should be strongly considered 1.

Special Populations

Elderly patients (≥75 years): Safety profiles appear similar to younger patients, with no significant difference in adverse event rates 3. However, these patients may have reduced physiologic reserve.

Poor performance status (PS≥2): While LFT abnormalities occur at similar rates, these patients have significantly worse progression-free survival and lower albumin levels, which independently predicts mortality 3. Lower albumin may affect drug pharmacokinetics and toxicity.

Common Pitfalls to Avoid

  • Don't ignore early AST elevations: AST rises significantly with enfortumab vedotin and may precede ALT changes 3
  • Don't assume all LFT elevations are drug-related: In oncology patients, disease progression is the most common cause 1
  • Don't use total bilirubin alone in Gilbert's syndrome: This leads to unnecessary treatment interruptions 1
  • Don't delay repeat testing: The 2-5 day window for reassessment is critical for catching rapidly progressive injury 1

Clinical Context

The FDA label confirms that liver function test changes are among the most common side effects with enfortumab vedotin 2. While dose reductions for toxicity may actually improve progression-free survival without compromising efficacy 5, the decision to reduce versus discontinue must be individualized based on the severity algorithm above and exclusion of alternative causes.

Related Questions

What is the appropriate workup for an adult with isolated total bilirubin elevation and otherwise normal CBC (complete blood count) and CMP (comprehensive metabolic panel)?
What is the appropriate next step in evaluating and managing a firefighter with an elevated alanine aminotransferase (ALT) and leukopenia?
How should a 32‑year‑old G2P1L1 woman at 33 weeks gestation presenting with fever, mild hemoptysis, significant weight loss, jaundice, pruritus, positive urine bile salts, elevated alkaline phosphatase, normal gamma‑glutamyl transferase, normal other liver enzymes, elevated bile acids, high erythrocyte sedimentation rate, pallor, and a past history of pulmonary tuberculosis be managed?
What is the appropriate evaluation and management for a 59-year-old man with mildly elevated total bilirubin, aspartate aminotransferase, and alanine aminotransferase?
What is the significance of an alanine aminotransferase of 163 U/L, aspartate aminotransferase of 142 U/L, and alkaline phosphatase of 165 U/L?
Does flucloxacillin provide adequate coverage for Clostridium tetani in the treatment of tetanus?
What does it mean when a standard echocardiogram shows normal left ventricular wall motion and normal left ventricular systolic function but the global longitudinal strain is –11%?
What is the appropriate deep vein thrombosis (DVT) prophylaxis regimen for adult hospitalized patients, including dosing, timing after major orthopedic surgery, renal dose adjustments, and recommendations for pregnant patients?
What is the treatment success rate of imiquimod (Aldara) for superficial basal cell carcinoma (sBCC) on the nose?
What key information should a respiratory therapist include in an ICU shift report when summarizing the day's patient care?
What are the recommended sick‑day management guidelines for a person with type 1 diabetes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.